0000899243-20-012881.txt : 20200512
0000899243-20-012881.hdr.sgml : 20200512
20200512200019
ACCESSION NUMBER: 0000899243-20-012881
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200511
FILED AS OF DATE: 20200512
DATE AS OF CHANGE: 20200512
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brown Bob D
CENTRAL INDEX KEY: 0001598479
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36281
FILM NUMBER: 20870716
MAIL ADDRESS:
STREET 1: 87 CAMBRIDGEPARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
FORMER NAME:
FORMER CONFORMED NAME: Brown Bob
DATE OF NAME CHANGE: 20140129
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dicerna Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001399529
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205993609
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 33 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617 621 8097
MAIL ADDRESS:
STREET 1: 33 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-11
0
0001399529
Dicerna Pharmaceuticals Inc
DRNA
0001598479
Brown Bob D
C/O DICERNA PHARMACEUTICALS, INC.
33 HAYDEN AVENUE
LEXINGTON
MA
02421
0
1
0
0
See Remarks
Common Stock
2020-05-11
4
M
0
13281
2.97
A
18281
D
Common Stock
2020-05-11
4
S
0
13281
24.00
D
5000
D
Employee Stock Option (Right to Buy)
2.97
2020-05-11
4
M
0
13281
0.00
D
2027-01-03
Common Stock
13281
31546
D
The reporting person sold an aggregate of 13,281 shares of common stock on May 11 2020 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 1.31% of 1,012,463 shares of common stock, which is the number of shares of common stock owned by the reporting person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the reporting person as of the date of this report.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2019.
The option vests in 48 monthly installments over the four-year period starting on the last day of January 2017, subject in each case to the reporting person's continued service with the issuer through the applicable vesting date.
Chief Scientific Officer, EVP of R&D
/s/ John B. Green, attorney-in-fact
2020-05-12